78% of Men Report Improved Libido on Testosterone Therapy

By VirentaNews Staff — May 12, 2026

In a quiet examination room at Massachusetts General Hospital, a 62-year-old man flips through photos on his phone—his daughter’s wedding from last summer, a hiking trip in the White Mountains with his wife. He smiles, but there’s a quiet tension in his voice as he admits he hasn’t felt truly present in months. After undergoing radical prostatectomy for early-stage prostate cancer, he lost his libido, struggled with fatigue, and found even climbing stairs left him winded. He’s not alone. While prostate cancer survival rates now exceed 99% for localized disease, the aftermath of surgery often brings an invisible burden: hormonal disruption, sexual dysfunction, and a diminished sense of self. Now, a groundbreaking clinical trial is offering hope—not just for physical recovery, but for reclaiming life after cancer.

Testosterone Therapy Shows Measurable Benefits

A randomized, double-blind, placebo-controlled trial led by Dr. Shalender Bhasin at Mass General Brigham has demonstrated that testosterone replacement therapy (TRT) significantly improves sexual function, physical strength, and mood in men who have undergone radical prostatectomy. Published in The New England Journal of Medicine, the study followed 132 men with confirmed testosterone deficiency after surgery. Half received weekly testosterone gel, the other half a placebo. After one year, the TRT group showed marked gains: 78% reported improved sexual desire and activity compared to 30% in the placebo group. Muscle mass increased by an average of 1.8 kilograms, while fat mass decreased. Participants also reported less fatigue and better overall mood. Crucially, no significant difference in prostate cancer recurrence was observed between groups over the 24-month follow-up, challenging decades of caution around testosterone use in prostate cancer survivors.

Overcoming Decades of Medical Hesitation

For years, medical guidelines have discouraged testosterone therapy in men with a history of prostate cancer, rooted in the 1941 discovery that androgens fuel prostate tumor growth. This led to the widespread use of androgen deprivation therapy (ADT) for advanced disease—and a lingering assumption that any testosterone exposure could reignite cancer. But as prostate cancer screening and treatment have evolved, so too has the understanding of risk. Most post-prostatectomy patients have low-grade, organ-confined cancer with minimal recurrence potential. Yet, many are left with symptomatic hypogonadism—low testosterone—without treatment options. The Bhasin trial breaks from this paradigm by rigorously testing TRT in a carefully selected population. By excluding men with high-risk features and monitoring PSA levels closely, the study provides the first high-quality evidence that TRT can be both safe and beneficial, even after a cancer diagnosis.

The Doctors and Patients Redefining Recovery

Dr. Shalender Bhasin, a leading endocrinologist and researcher in male reproductive health, has spent over three decades investigating the physiological impacts of testosterone. His motivation stems from seeing patients dismissed as “just aging” when their symptoms were biochemical and treatable. “We’ve pathologized normal aging while ignoring treatable hormone deficiency,” he said in a recent interview. Patients in the trial echoed this sentiment—many had been told their fatigue and sexual decline were inevitable. One participant, a former high school coach, described feeling “like a ghost in my own life.” With TRT, he regained energy, resumed weight training, and reconnected with his partner emotionally and physically. These personal transformations underscore a shift: recovery from cancer is not just about survival, but about quality of life.

Implications for Patients and Clinicians

The study’s findings could reshape clinical practice for thousands of men annually. In the U.S., over 100,000 men undergo radical prostatectomy each year, and a substantial proportion develop persistent testosterone deficiency. Until now, many have been denied TRT out of caution. This trial provides evidence to reconsider that stance—particularly for low-risk patients with documented hypogonadism. Experts urge caution, however: TRT should only be considered after thorough risk stratification, including Gleason score, surgical margins, and PSA monitoring. For eligible men, the benefits may extend beyond sexual function to include improved metabolic health, bone density, and mental well-being. Insurance coverage and access remain hurdles, but advocacy groups are pushing for updated guidelines from bodies like the Endocrine Society and the American Urological Association.

The Bigger Picture

This study is part of a broader reevaluation of how medicine treats survivorship. As cancer outcomes improve, the focus must shift from mere survival to holistic recovery. Denying effective treatments due to outdated fears does a disservice to patients who’ve already endured significant physical and emotional trauma. The success of TRT in this context also highlights the need for personalized, evidence-based approaches in endocrinology and oncology. Just as cancer treatment has moved toward precision medicine, so too must supportive care evolve—tailoring interventions to individual risk and need.

What comes next is not a blanket recommendation, but a call for dialogue. Clinicians must engage patients in shared decision-making, weighing risks and benefits with up-to-date evidence. Future research will explore longer-term outcomes and the effects of TRT in men with higher-risk profiles. For now, this trial offers a powerful message: recovery after prostate cancer can include vitality, intimacy, and strength—elements not just of living, but of truly thriving.

Source: MedicalXpress